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Abstract
INTRODUCTION: The expression, mechanisms of regulation, and functional impact of INHBA (activin A) in lung adeno-
carcinoma (AD) have not been fully elucidated. METHODS: INHBA expression was examined in 96 lung samples
(86 ADs, 10 normal lung) using oligonucleotide microarrays and 187 lung samples (164 ADs, 6 bronchioalveolar
carcinomas, and 17 normal lung) using immunohistochemistry. The proliferation of AD cell lines H460 and SKLU1
was examined with WST-1 assays after treatment with recombinant activin A, follistatin, and INHBA-targeting
small-interfering RNA. Cells were also treated with 5-aza-2′ deoxycytidine and trichostatin A to investigate the role
of epigenetic regulation in INHBA expression. RESULTS: Primary ADs expressed 3.1 times more INHBA mRNA than
normal lung. In stage I AD patients, high levels of primary tumor INHBA transcripts were associated with worse prog-
nosis. Immunohistochemistry confirmed higher inhibin βA protein expression in ADs (78.7%) and bronchioalveolar
carcinomas (66.7%) compared with normal lung (11.8%). H460 and SKLU1 demonstrated increased proliferation
when treated with exogenous activin A and reduced proliferation when treated with follistatin or INHBA-targeting
small-interfering RNA. INHBA mRNA expression in H460 cells was upregulated after treatment with trichostatin A
and 5-aza-2′ deoxycytidine. CONCLUSIONS: INHBA is overexpressed in AD relative to controls. Inhibin βA may pro-
mote cell proliferation, and its overexpression is associated with worse survival in stage I AD patients. In addition,
overexpression of INHBA may be affected by promoter methylation and histone acetylation in a subset of lung ADs.
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Introduction
Lung cancer is currently the leading cause of cancer death in indus-
trialized nations, with an overall 5-year survival of 15.5% [1]. Among
non–small cell lung cancer variants, adenocarcinoma (AD) is the
most common histologic subtype. Gene expression profiling has al-
lowed for the simultaneous analysis of thousands of genes, and has
been used to correlate lung AD expression patterns with clinical out-
comes [2–4]. Elucidation of the molecular pathways that stimulate
the development of lung AD will allow for improvements in preven-
tion, diagnosis, and prognostication.
Inhibin βA (INHBA) is a ligand in the transforming growth factor β
(TGF-β) superfamily [5]. Inhibin βA forms a disulfide-linked homo-
dimer known as activin A, which was originally described in 1978 for
its role in the hypothalamic-pituitary-gonadal axis [6,7]. Since that
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time, activin A has been implicated in multiple biologic processes, in-
cluding neoplastic progression [8–13]. The inhibin βA subunit may
also dimerize with the inhibin βB and inhibin α isoforms to form ac-
tivin AB and inhibin A, respectively.
Overexpression of activin A in esophageal squamous cell carci-
noma has been associated with advanced nodal status, clinical stage,
and a worse overall prognosis [11]. In addition, chronic exposure to
activin A promotes growth, tumorigenicity, invasion, and resistance
to apoptosis in esophageal squamous cell carcinoma [12]. Inhibin α–
knock-out mice express high levels of serum activin A and almost
uniformly develop gonadal stromal tumors, supporting the role of
activin A overexpression in tumorigenesis [13]. Furthermore, overex-
pression of activin A has been reported in colon, prostate, pancreatic,
and ovarian cancers [14–17], and women with endometrial or cervi-
cal cancer exhibit elevated serum concentrations of activin [18]. How-
ever, the pleiotropic capabilities of activin A are evidenced by its
growth-inhibitory effects on prostate cancer cells, vascular endothelial
cells, mammary epithelial cells, plasmacytomas, and hepatocytes [19–
24]. Activin A has also been shown to induce endodermal differen-
tiation in human embryonic stem cells [25].
The role of INHBA in the pathogenesis of lung AD has not been
fully elucidated. A recent study found that INHBA was one of 26
significantly mutated genes in lung AD and that INHBA mutation
frequency correlated with tumor grade, suggesting a role in tumor
progression [26]. Here, we demonstrate that INHBA is overexpressed
in >70% of lung AD and that transcript expression inversely corre-
lates with survival in patients with stage I disease. Our data also sug-
gest that lung AD cell proliferation may be partially dependent on
the presence of activin A. Finally, we provide evidence that an upreg-
ulated expression of INHBA in lung AD cells may be related to pro-
moter demethylation and histone acetylation.
Materials and Methods
Patients and Tissues
The oligonucleotide microarray and tissue microarray (TMA) lung
specimens were obtained from consented patients with either stage I
or stage III primary lung AD who underwent surgery at the Univer-
sity of Michigan Health System between 1994 and 2000. Approval
for this study was obtained by the local institutional review board.
Tissues were transported on ice in Dulbecco’s modified Eagle’s me-
dium (DMEM; Life Technologies, Inc, Carlsbad, CA), immediately
frozen in liquid nitrogen, and stored at −80°C. Tissues demonstrat-
ing AD and at least 70% cellularity were identified on hematoxylin
and eosin–stained frozen sections. Macrodissection was used to ob-
tain samples 2 to 3 mm3 in size for RNA and protein isolation. The
histologic diagnosis of each specimen was independently confirmed
by two pathologists (T.J.G and D.G.T). Patients with stage I disease
received surgery alone, whereas patients with stage III disease re-
ceived surgery plus neoadjuvant chemotherapy and radiotherapy.
Cell Lines
The cell lines used in this study, H460 and SKLU1, were derived
from lung AD, and have been previously described [27,28]. Both cell
lines were maintained in DMEM (Invitrogen Corp., Carlsbad, CA)
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin/
fungizone (Life Technologies, Inc) at 37°C in 5% CO2. Cells were
treated at 70% confluence.
Oligonucleotide Microarray
The RNA was isolated, cRNA was synthesized, and oligonucleo-
tide microarrays were analyzed as previously described [29]. Results
from this data set have been previously published elsewhere [2].
Immunohistochemistry of Tissue Microarray
Immunohistochemical staining was performed on the DAKO
Autostainer (DAKO, Carpinteria, CA) using DAKO LSAB+ and di-
aminobenzadine as the chromogen, as previously described [29]. De-
paraffinized sections of the TMA at 5-μm thickness were labeled
with inhibin βA antibody (catalog no. MAB3381; R&D Systems,
Minneapolis, MN; mouse, 1:20) after microwave antigen retrieval in
10 mM sodium citrate buffer, pH 6. Negative (no primary antibody)
and positive (placenta) controls were used. The intensity and extent of
immunoreactivity were scored using a three-tier (negative [−], moder-
ate [1+], and intense [2+]) grading scheme. All tissues were examined
using an Olympus BX40 microscope (Olympus, Center Valley, PA).
Images were acquired using a Spot Insight model 3.2.0 camera (Diag-
nostic Instruments, Inc, Sterling Heights, MI) and Spot version 4.0.9
(Diagnostic Instruments, Inc) software.
Immunohistochemistry of Cell Lines
After plating on poly-L-lysine–coated glass slides, cells were air-
dried and fixed in −20°C acetone for 10 minutes. Endogenous per-
oxidases were inactivated using 0.5% hydrogen peroxide. Cells were
stained with the Vectastain ABC Kit (catalog no. PK-6102, mouse
IgG; Vector Laboratories, Burlingame, CA) and Peroxidase Substrate
Kit (catalog no. SK-4100; Vector Laboratories) according to the man-
ufacturer’s instructions. Inhibin βA antibody (catalog no. MAB3381;
R&D Systems) at a concentration of 1:20 was used as the primary
antibody. Negative controls (no primary antibody) were stained with
each immunohistochemical assay.
Western Blot Analysis
Western blot analysis was performed as previously described with
slight variations [30]. Briefly, 15 μl of FBS or calf serum (CS) was
loaded onto a 10% SDS–polyacrylamide gel and electrophoresed. A
1:200 (2 μg/ml) concentration of inhibin βA antibody (catalog no.
MAB3381; R&D Systems) and a 1:10,000 concentration of second-
ary antibody (catalog no. NA931V, goat antimouse; GE Healthcare
UK Limited, Chalfont St. Giles, United Kingdom) were used for
protein detection.
Real-time Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted using the RNeasy Mini Kit (catalog no.
74104; Qiagen, Valencia, CA), and cDNA was created using the Su-
perscript II Kit (catalog no. 18064; Invitrogen) according to the man-
ufacturer’s instructions. Real-time reverse transcription–polymerase
chain reaction (RT-PCR) was performed using the Rotor-Gene 6000
(Corbett Life Science, Sydney, Australia) with the Platinum SYBR
Green kit (catalog no. 11733-038; Invitrogen). The INHBA oligo pri-
mers for real-time RT-PCR were obtained from Invitrogen and in-
cluded forward INHBArt2f (5′-AAG TCG GGG AGA ACG GGT
ATG TGG-3′) and reverse INHBArt2r (5′-TCT TCC TGG CTG
TTC CTG ACT CG-3′). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH ) expression was used to standardize the INHBA results using
GAPDH primers obtained from Invitrogen. Optimal annealing tem-
peratures were determined, and melt curves were analyzed to ensure
RT-PCR results.
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WST-1 Cell Proliferation Assays
Cell viability and proliferation were assessed using Cell Prolifera-
tion Reagent WST-1 (catalog no. 11644807001; Roche Applied Sci-
ence, Indianapolis, IN) according to the manufacturer’s instructions.
The experiments were performed in 96-well plates at two different
cell densities. H460 cells were plated at 1.0 × 103 and 2.0 × 103 cells
per well, whereas SKLU1 cells were plated at 1.5 × 103 and 2.5 ×
103 cells per well. Absorbance was measured on a Biotek EL-312e
microplate reader (Biotek Instruments, Winooski, VT) at 96 hours.
All activin A and follistatin treatment experiments were performed
in quadruplicate.
Treatment of H460 and SKLU1 with Activin A
and Follistatin
Twenty-four hours after plating, H460 and SKLU1 cells were treated
with 1, 10, and 100 ng/ml recombinant activin A (catalog no. 120-
14; Peprotech, Inc, Rocky Hill, NJ) in DMEM with 10% FBS or
10% CS. Similarly, H460 and SKLU1 were treated with 1, 10, and
100 ng/ml follistatin (catalog no. 120-13; Peprotech, Inc) in DMEM
with 10% FBS.
Transfection of H460 Cells with INHBA-targeting
Small-interfering RNA
Transient transfection of H460 cells with INHBA-targeting small-
interfering RNA (siRNA) was performed as previously described [31].
Briefly, H460 cells were trypsinized at 70% confluence and plated at
a density of 2.0 × 103 cells per well in DMEM with 10% FBS in a
96-well format for determination of the optimal siRNA transfection
concentration. Twenty-four hours after plating, cells were treated with
INHBA-targeting SMART pool siRNA (Dharmacon, Lafayette, CO)
in the presence of 0.1 μl of Lipofectamine RNAiMAX (Invitrogen) in
9.9 μl of Opti-MEM I (Invitrogen). INHBA knockdown efficiency
was determined by real-time RT-PCR. An optimal working concen-
tration of 10 nM siRNA was used to perform WST-1 cell prolifera-
tion assays. Forty-eight hours after initial transfection, half of the
plates were transfected with a second dose of 10 nM INHBA-targeting
siRNA. Transfected cells were incubated for a total of 96 hours at 37°C
before gene silencing analysis. Cells treated only with transfection re-
agent were used as a control. All siRNA transfection experiments were
performed in quadruplicate.
Treatment of H460 and SKLU1 with Trichostatin A and
5-Aza-2′ Deoxycytidine
H460 and SKLU1 cells were serum-starved for 24 hours before
treatment to synchronize cell cycles. Cell lines were then treated with
trichostatin A (TSA) at a final concentration of 300 nM or with 5-
aza-2′ deoxycytidine (5-AZA) at a final concentration of 5 μM in
DMEM with 10% FBS. Cells receiving combination treatment were
exposed to both 300 nM TSA and 5 μM 5-AZA. Trichostatin A and
5-AZA were dissolved in DMSO (catalog no. D4540; Sigma Aldrich,
St. Louis, MO), and control cells were treated with equivalent
amounts of DMSO. Cells treated with TSA were trypsinized and
harvested at 12 and 24 hours, and those treated with 5-AZA were
harvested at 48, 72, and 96 hours. Combination plates were treated
with 5-AZA for 48, 72, or 96 hours and TSA for 24 hours. Cell pel-
lets for mRNA analysis were frozen in liquid nitrogen and stored in
−80°C until mRNA was extracted for real-time RT-PCR. All experi-
ments examining the effects of TSA and 5-AZA were performed in
duplicate. Cells for immunohistochemistry (IHC) analysis were im-
mediately suspended in PBS and plated on poly-L-lysine–coated
slides using a Shandon Cytospin 3 machine (Thermo Fisher Scien-
tific, Waltham, MA).
Correlation between INHBA and Histone Deacetylase,
Histone Acetyltransferase, and DNA
Methyltransferase Expression
To support a role of histone acetylation and promoter methylation
in the regulation of INHBA expression, we examined the oligonu-
cleotide microarray expression of histone deacetylases (HDACs),
histone acetyltransferases, and DNA methyltransferases (DNMTs).
However, the Affymetrix HuFL microarray (Affymetrix, Santa Clara,
CA) [2] included only one DNMT and three HDAC probe sets:
DNMT1, HDAC1, HDAC2, and HDAC3. Therefore, we repeated
the analysis with two publicly available expression data sets that used
the Affymetrix HG-U133A oligonucleotide microarray. These data
were obtained from the Gene Expression Omnibus [32]. One of
the data sets used included primary lung AD and normal lung tissue
[33], whereas the second included primary lung AD and lung squa-
mous cell carcinomas [34]. For the first data set, all normal lung tis-
sue data were excluded, and for the second data set, all squamous cell
carcinoma data were excluded before analysis.
Statistical Analysis
Kaplan-Meier survival curves and the log-rank test were used to
determine the association between patient survival and INHBA ex-
pression. The t-test was used to determine the significance of changes
in proliferation associated with treatment. Spearman analysis was
used to correlate INHBA gene expression with that of the HDACs,
histone acetyltransferases, and DNMTs. P < .05 was deemed signif-
icant. All statistical analyses were performed using R version 2.7.0
(Vienna, Austria).
Results
INHBA Is Overexpressed in Lung AD and Correlates with
Worse Outcome in Stage I Disease
Affymetrix oligonucleotide microarrays were used to measure INHBA
expression in 86 AD and 10 normal lung samples (Figure 1A). Two-
fold more INHBA mRNA was detected relative to the mean of the
normal lung tissue in 61 (70.9%) of 86 samples and at least four-fold
more in 17 (19.7%) of 86 samples. On average, the AD samples
contained 3.1-fold more INHBA transcripts than the normal lung
tissue samples (67.2 vs 21.8, P = .001).
Kaplan-Meier survival analysis of the 66 stage I patients demon-
strated that patients with high levels of INHBA transcripts (greater
than median = 57.6; n = 33) had a significantly worse prognosis than
those with low levels (less than median = 57.6; n = 33; P = .008; Fig-
ure 1B). The number of stage IA and IB patients was approximately
equal between the low and high INHBA-expressing groups (23 low IA
vs 20 high IA; 10 low IB vs 13 high IB). INHBA mRNA expression
was not related to survival in the 20 stage III patients (P = .3).
Inhibin βA Expression Confirmed on Lung TMA
Immunohistochemical staining of a TMA containing 164 AD,
6 bronchioalveolar carcinoma (BAC), and 17 normal lung samples
showed higher inhibin βA expression in AD and BAC relative to that
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of normal lung. All inhibin βA staining was noted to be cytoplasmic,
and no correlation was noted between the intensity of staining and
the differentiation or histologic subtype of AD. Immunoreactivity was
found in 78.7% (moderate: 129/164, intense: 20/164) of AD (Fig-
ure 2, C and D) and 66.7% (moderate: 2/6, intense: 2/6) of BAC
(Figure 2B). Only 11.8% (moderate: 2/17) of normal lung samples
demonstrated inhibin βA staining, with no normal lung samples dem-
onstrating intense staining (Figure 2A).
Activin A Induced Proliferation in H460 and SKLU1 Cells
Adenocarcinoma cell lines H460 and SKLU1 treated with recombi-
nant activin A at concentrations ranging from 1 to 100 ng/ml demon-
strated increased proliferation relative to untreated controls at 96 hours.
The effect of activin A treatment was greater in the presence of CS
than in the presence of FBS in both cell lines. H460 cells demon-
strated the greatest growth-proliferative response after treatment with
100 ng/ml activin A in CS (180%) and with 10 ng/ml activin in FBS
(163%; Figure 3A). Treatment of SKLU1 cells with 100 ng/ml acti-
vin A induced the greatest growth-proliferative response in both CS
and FBS, at 157% and 112% relative to controls, respectively (Fig-
ure 3B). The growth-proliferative response was inversely related to
the baseline INHBA transcript expression as assessed by real-time
RT-PCR. H460 cells demonstrated low INHBA transcript levels
(C t = 26.6, GAPDH = 11.8), whereas SKLU1 cells had moderate
INHBA transcript expression (C t = 18, GAPDH = 10.6). At baseline,
neither H460 nor SKLU1 cells demonstrated inhibin βA immuno-
reactivity on Western blot or IHC.
Inhibin βA Is More Abundant in FBS Than CS
We suspected that the attenuated growth response seen in FBS
with activin A treatment was due to a higher inhibin βA concentra-
tion in FBS than CS. On Western blot analysis, inhibin βA was seen
in all four replicate FBS lanes but in none of the four CS lanes, sug-
gesting a higher concentration of activin A in FBS than in CS. This
finding was replicated and confirmed with different batches of FBS
and CS (data not shown).
Figure 1. (A) Affymetrix oligonucleotide microarray analysis of 86 lung AD (AD) and 10 nontumor control specimens demonstrated at
least a two-fold increase in expression in 61 (70.9%) of 86 and a four-fold increase in expression in 17 (19.7%) of 86 lung AD relative to
controls. The x-axis represents tumor identifier. (B) Kaplan-Meier survival analysis of 66 stage I lung AD demonstrated reduced survival in
patients with high INHBA expression.
Neoplasia Vol. 11, No. 4, 2009 Importance of INHBA Expression in Lung Adenocarcinoma Seder et al. 391
Inhibin βA Inhibitor Follistatin Reduces Proliferation in
H460 and SKLU1 Cells
AD cell lines H460 and SKLU1 treated with activin A inhibitor
follistatin at a concentration ranging from 1 to 100 ng/ml demon-
strated modestly reduced cell proliferation relative to untreated con-
trols at 96 hours. The greatest growth-inhibitory response in H460
cells was demonstrated with 1 ng/ml follistatin (80%). Higher
concentrations did not further reduce cell growth (Figure 4A). Con-
versely, treatment of SKLU1 cells with follistatin inhibited prolifera-
tion in a dose-dependent manner, with the greatest reduction seen at
100 ng/ml (Figure 4B).
Transfection of H460 with INHBA-Targeting siRNA Reduces
INHBA Expression and Cell Proliferation
As assessed using real-time RT-PCR, an INHBA-silencing efficiency
of 93% relative to mock controls was achieved by transfecting H460
cells with INHBA-targeting siRNA at a concentration of 10 nM. This
concentration of INHBA-targeting siRNA produced a 6% reduction
in proliferation at 96 hours. When cells were retransfected 48 hours
after the initial transfection, an 11% reduction in proliferation was ob-
served at 96 hours (Figure 4C).
Epigenetically Mechanisms May Influence INHBA Expression
in Lung AD Cell Lines
We treated H460 and SKLU1 cells with 5-AZA and TSA to de-
termine whether epigenetic regulation influenced INHBA expression.
H460, a cell line with low baseline INHBA expression, demonstrated
a 15.7-fold (range, 13.4- to 18-fold) increase in mRNA production
relative to the mean of the controls with 24 hours of TSA exposure
(Figure 5A). When cells were treated with a combination of TSA
for 24 hours and 5-AZA for 72 hours, an 86.5-fold (range, 79.3-
to 93.7-fold) increase in INHBA mRNA expression was observed.
SKLU1 cells, which demonstrated higher baseline INHBA expres-
sion, showed a blunted INHBA up-regulation on treatment with TSA
and 5-AZA (Figure 5B). Treatment with TSA and 5-AZA, alone or
in combination, induced a 1.2- to 5.2-fold increase in SKLU1 INHBA
mRNA production. The INHBA mRNA up-regulation observed in
the H460 and SKLU1 cells were not able to be demonstrated onWest-
ern blot or IHC.
Correlation between INHBA and DNMT1 and
HDAC6 Expression
We compared the expression of DNMT1, HDAC1, HDAC2, and
HDAC3 on the original oligonucleotide microarray with INHBA ex-
pression using Spearman correlation analysis. DNMT1 was found to
have a strong negative correlation with INHBA expression (P = .003).
However, no HDACs included on the microarray correlated with
INHBA expression. We then performed the analysis using two pub-
licly available Affymetrix HG-U133A lung cancer data sets. DNMT1
was confirmed to have a significant negative correlation with INHBA
expression in the first lung AD data set [32] (P = .026, n = 58). In ad-
dition, significantly negative correlations were found between INHBA
and HDAC6 expression in both data sets [32,33] (P = .014 and P =
.029 [n = 60], respectively).
Discussion
We have demonstrated that INHBA mRNA and protein are over-
expressed in primary lung AD relative to normal lung tissue. On
Kaplan-Meier analysis, the level of INHBA mRNA expressed by
primary ADs inversely correlates with patient survival in stage I dis-
ease. The prognostic capability of INHBA may be related to the pro-
liferative effect activin A exposure has on AD cells. Furthermore,
Figure 2. Representative sections of TMA. Inhibin βA protein stain-
ing was not detected in normal lung tissues (A) but was seen in
66.7% (4/6) of BAC (B) and in 78.7% of lung AD by IHC (C and D).
Original magnification, ×40.
Figure 3. H460 (A) and SKLU1 (B) cells treated with recombinant
activin A demonstrated increased proliferation at 96 hours. The ef-
fect of activin A treatment was greater in the presence of CS than
in the presence of FBS. *P < .05.
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AD activin dependency is suggested by the decrease in prolifera-
tion seen with follistatin and INHBA-targeting siRNA treatment in
AD cell lines.
Interestingly, exposure of H460 cells to high doses of exogenous
activin A in the presence of FBS resulted in a blunted proliferative
response. This effect was not seen when the cells were treated in the
presence of CS, which, unlike FBS, contains no detectable activin A
by Western blot. These findings suggest that at high concentrations,
activin A might exert growth-inhibitory effects on some cell lines. Ac-
tivin A’s complex function is characteristic of members of the TGF-β
superfamily, which are known to have both tumor suppressive and
oncogenic effects. In the current paradigm, the tumor suppressor
activities of the TGF-β cascade dominate in normal tissues, but dur-
ing tumorigenesis, changes in cellular response may promote onco-
genesis [35,36]. Activin A seems to exert a similar dose-dependent
dual effect on H460 cells, which do not express large amounts of ac-
tivin A. The moderate INHBA-expressing cell line, SKLU1, demon-
strated a less pronounced proliferative response when treated with
activin A. However, the growth-proliferative effects of activin are seen
in a dose-dependent manner, suggesting that SKLU1 cells tolerate
higher concentrations of activin without growth inhibition.
Although the levels of specific growth factors are not available for
most commercially obtained serums, multiple studies have demon-
strated that the concentration of activin A rises during pregnancy
in maternal serum and is detectable at high levels in amniotic fluid
and fetal serum [37–43]. In addition, studies have shown that de-
letion of INHBA in mice results in severe craniofacial abnormalities,
including cleft palate and lack of lower incisors. Furthermore, lack of
type IIA activin receptors in fetal mice results in impaired reproduc-
tive function [44,45]. Such evidence implicates the role of activin A
Figure 4. H460 (A) and SKLU1 (B) cells treated with activin inhibitor follistatin demonstrated modestly reduced proliferation at 96 hours.
(C) H460 cells treated with 10 nM INHBA-targeting siRNA demonstrated reduced cell proliferation at 96 hours relative to mock controls.
Repeat transfection 48 hours after initial transfection resulted in further growth inhibition relative to controls.
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in fetal development and is consistent with our Western blots dem-
onstrating the presence of inhibin βA in FBS.
Follistatin is a 32- to 39-kDa monomeric protein that was first
identified as a potent inhibitor of pituitary follicle-stimulating hor-
mone secretion [46] and subsequently found to serve as an activin
A–binding compound [47]. Follistatin binds activin A with high af-
finity (50-500 pM) to form inactive complexes, thereby regulating
the function of activin A [48]. When we treated H460 and SKLU1
cells with follistatin, a moderate decrease in proliferation was seen
in both cell lines, which was consistent with activin A inhibition. We
confirmed the growth-inhibitory effects of activin A inhibition by treat-
ment of H460 with INHBA-targeting siRNA. Although follistatin does
bind activin B and some members of the bone morphogenetic protein
family with very low affinity and siRNA transfection has the potential to
exert off-target effects, our data consistently demonstrated a reduction in
cell growth with differing methods of activin A inhibition. The growth
reduction consistently seenwith activin A inhibition suggests that agents
targeting INHBA may be therapeutically useful.
The inhibin βA subunit may also dimerize with inhibin α and in-
hibin βB subunits to form inhibin A and activin AB, respectively.
Within the reproductive axis, inhibin A and activin A oppose each
other in the control of steroid, androgen, and placental hormone pro-
duction [49]. Interestingly, on oligonucleotide microarray analysis,
our ADs expressed approximately half the α subunit mRNA tran-
scripts as the normal tissue samples. In addition, a direct correlation
was identified between survival and α subunit expression when the
66 stage I ADs (P = .017) and all 86 ADs (P = .008) were examined.
Assuming inhibin A and activin A are similarly antagonistic in the
regulation of AD growth, these correlations may represent inhibition
of activin A’s proliferative effect on AD cells.
INHBA mRNA expression has prognostic significance in patients
with stage I AD, but not stage III AD, most likely because medi-
astinal lymph node spread is a stronger predictor of survival than
primary tumor growth rate. Perhaps, by the time that AD gain meta-
static potential, the proliferative rate of the primary tumor, which
INHBA expression may be associated with, does not alter outcome.
The prognostic significance of INHBA mRNA expression in stage I
AD, combined with its growth-proliferative effects in two AD cell
lines, prompted us to explore potential mechanisms for overexpres-
sion. Previous reports have established that epigenetic mechanisms
affect patterns of gene expression in normal and neoplastic tissues
[50,51]. Our cell line work and microarray correlation data suggest
that the overexpression seen in a subset of primary tumors might be
due to histone acetylation and/or promoter demethylation. The
greatest increase in INHBA mRNA expression occurred in the low-
INHBA expressing cell line, H460, after a combination of 72 hours
of 5-AZA and 24 hours of TSA exposure. Treatment of H460 with
5-AZA beyond 72 hours, alone or in combination with TSA, led to a
smaller increase in INHBA expression. Because 5-AZA is a global de-
methylating agent, prolonged exposure may also affect promoters of
other genes that result in the down-regulation of INHBA transcrip-
tion. The overall blunted up-regulation of INHBA transcription seen
in SKLU1 compared with H460 may be a reflection of its higher
baseline expression, thus resulting in a smaller fold increase.
Although 70% to 80% of primary AD overexpressed INHBA
mRNA and protein, inhibin βA immunoreactivity was not observed
Figure 5. INHBA mRNA expression in H460 (A) and SKLU1 (B) cells was upregulated on treatment with HDAC inhibitor TSA and de-
methylating agent 5-AZA. “Both” refers to the combination of TSA and 5-AZA treatment.
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on Western blot or IHC of H460 and SKLU1 cells treated with TSA
and 5-AZA. The basis for this difference is not clear; however, the
low-to-moderate baseline production of INHBA in both cell lines
may allow for a significant relative up-regulation of mRNA but an
absolute increase that does not translate into a detectable difference
in protein production. Our inability to detect the up-regulation of
inhibin βA protein in the cell lines may also be related to the soluble
nature of activin A and its known secretion from the cell. Differences
between the in vivo and in vitro microenvironment may also play a
role and posttranscriptional interference. Forty-nine microRNA are
predicted to bind to the INHBA mRNA, suggesting an area for fu-
ture investigation [52].
INHBA may represent a novel target in the treatment of lung AD.
It is clear that INHBA overexpression is not the sole mechanism for
the uncontrolled growth of lung AD because some ADs do not ex-
press high levels of INHBA and inhibition of INHBA does not fully
arrest AD growth. However, our data suggest that activin A exposure
does promote proliferation and that lung AD cells are partially de-
pendent on activin A exposure. Activin-binding agents, such as fol-
listatin, monoclonal antibodies, and small molecule inhibitors, all
hold therapeutic potential, especially in combination with other
treatments. However, because INHBA is expressed in a wide array
of human tissues and has diverse biologic functions, the feasibility
of systemic therapy needs further investigation before in vivo appli-
cation. This study provides data to support continued investigation
into the role of INHBA in the progression of lung AD.
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